Advertisement Sagent launches Vancomycin hydrochloride for injection, USP - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sagent launches Vancomycin hydrochloride for injection, USP

US-based Sagent Pharmaceuticals has introduced Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10g preservative-free pharmacy bulk package.

The Vancomycin 10g package is an addition to the company’s Vancomycin 5g pharmacy bulk package offering.

The product is indicated to treat serious or severe infections caused by susceptible strains of methicillin-resistant (ß-lactam-resistant) staphylococci.

The US market for Vancomycin was approximated to be $196m for the 12 months ending February 2015, of which more than 50% of the sales was pharmacy bulk package bottles, according to IMS.

As with all products in the company portfolio, Vancomycin features PreventIV MeasuresSM packaging and labeling, which is designed to help reduce medication errors.

The product is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.